Deals

Oramed Pharmaceuticals Raises Capital with Unit Offering

By |

Oramed Pharmaceuticals (ORMP) announced that it has raised $5 million in a Unit (Common Stock and Warrants) transaction. The common stock was sold at $0.37 per share, an approximate 16% premium to the market price ($0.32) of ORMP at deal announcement. A series of 6,823,938 60-Month Warrants with an exercise price of $0.50 per share (56.25% premium) was issued to the investors in this transaction. The transaction closed in multiple tranches with the final tranche occuring on December 11, 2012. See the PlacementTracker Deal Summary.

Deals

Arrowhead Research in $4M CMPO

By |

Therapeutics developer Arrowhead Research Corp. (ARWR) announced that it has raised $4 million in a CMPO/Overnight transaction. The common stock was sold at $2.26 per share, an approximate 3% premium to the market price ($2.20) of ARWR at deal announcement. A series of 900,000 60-Month Warrants with an exercise price of $2.20 per share (0% premium) was issued to the investors in this transaction. Dawson James Securities, Inc. acted as the exclusive agent on the transaction.

Deals

Craig-Hallum Places Catasys Common

By |

Healthcare data management provider Catasys (CATS) announced that it has raised $3.29 million in a Common Stock transaction with investor Crede CG II. The common stock was sold at $0.07 per share, an approximate 42% discount to the market price ($0.12) of CATS at deal announcement. A series of 46,978,574 60-Month Warrants with an exercise price of $0.07 per share (41.67% discount) was issued to the investors in this transaction. Craig-Hallum Capital Group acted as financial adviser on the transaction. Issuer counsel was Mintz, Levin, Cohn, Ferris, Glovsky & Popeo.

Deals

Registered Direct from Durect Corp.

By |

Pharmaceutical drug delivery system designer Durect Corp. (DRRX) announced that it has raised $12.6 million in a Registered Direct transaction. The common stock was sold at $0.90 per share, an approximate 7% discount to the market price ($0.97) of DRRX at deal announcement. Stifel Nicolaus Weisel acted as the exclusive agent on the transaction. Placement Agent counsel was Cooley, and issuer counsel was Morrison & Foerster.